Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) --  Purple Biotech Ltd. ("Purple...

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors New preclinical data from study presented at the American Association for Cancer Research 2023 Annual Meeting, 18 April 2023 REHOVOT, Israel, April 19, 2023 (GLOBE NEWSWIRE) -- Purple Biotech...